Following weight changes in adults with severe obesity treated with semaglutide in France
Follows weight and well-being in adults with severe obesity treated with semaglutide.
Plain-language title generated from the registry record
Registry title: Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Key facts
- Where
- Nantes, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with obesity who were treated with WEGOVY in France's early access programme and can fill in an online questionnaire.
- Age
- 18 years or older
- Sex
- All sexes can join
- Earlier treatment
- Must have been in the ATU/early access programme for WEGOVY with at least two dispenses of WEGOVY
Main reasons for not taking part
- Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection
- Patients who object to the use of their data
- Patients who cannot complete an online questionnaire
Read by machine on 12 November 2026.
Where in France
- Nantes University HospitalNantes, FranceContact: David JACOBINo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nantes University Hospital
- Trial code
- NCT07423481
- Record updated
- 18 September 2026
- Original description
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.Read full original descriptionShow less
SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Inclusion: Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY; No objection to the use of their data; Patients able to complete an online questionnaire (via the internet).
Exclusion: Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection.